We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VISEN Pharmaceuticals

News List

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China prnasia
January 11, 2021
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China prnasia
January 08, 2021
VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market and hoping to provide more Chinese patients quick access to the ...